About
Four Projects
Combatting antimicrobial resistance; COMBACTE battles antimicrobial resistance by speeding up the development of new antibiotics. There are four main projects, each focused on a specific domain.
COMBACTE-NET
COMBACTE-NET is building strong clinical, laboratory and research networks. Enabling more efficient testing of novel antimicrobial drugs. And performing trials.
COMBACTE-MAGNET
COMBACTE-MAGNET focuses on critically ill patients in intensive-care units. And on the Gram-negative bacteria that cause most ICU-associated infections.
COMBACTE-CARE
COMBACTE-CARE is dedicated to meet the challenge of carbapenem-resistant bacteria. Laying the groundwork for tests of new and more effective treatments.
COMBACTE-CDI
COMBACTE-CDI’s primary goal is to develop a detailed understanding of the epidemiology and clinical impact of Clostridium difficile infection across Europe.
Four Networks
The backbone of all COMBACTE-projects consists of four specialized European networks
Partners
-
Academisch Medisch Centrum bij de Universiteit van Amsterdam
-
Academisch Ziekenhuis Groningen
-
AiCuris Anti-infective Cures GmbH
-
AO Documentation and Publishing Foundation, Clinical Investigation and Documentation
-
Aridis Pharmaceuticals
-
Assistance Publique – Hôpitaux de Paris
-
AstraZeneca AB
-
Basilea Pharmaceutica International AG
-
bioMerieux
-
Bristol University
-
Cardiff University
-
Centre Hospitalier Régional Universitaire de Besançon
-
Centre Hospitalier Universitaire de LIMOGES
-
Centre Hospitalier Universitaire de Poitiers
-
The Chancellor, Masters and Scholars of the University of Oxford
-
CHU de Pointe-à-Pitre
-
Cliniques Universitaires Saint Luc
-
Consorci Institut D’Investigacions Biomediques August Pi i Sunyer
-
DaVolterra
-
Eberhard Karls Universitaet Tuebingen
-
Erasmus Universitair Medisch Centrum Rotterdam
-
Ernst Moritz Arndt University Greifswald
-
European Clinical Research Infrastructure Network
-
European Forum for Good Clinical Practice
-
Fondation de Coopération Scientifique
-
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
-
Penta – Child Health Research
-
FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL BARCELONA
-
GlaxoSmithKline Biologicals S.A
-
GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LTD
-
The Health Corporation – RAMBAM
-
HELMHOLTZ-ZENTRUM FUER INFEKTIONSFORSCHUNG GMBH
-
Hospices Cantonaux CHUV
-
Hospital Universitario Son Espases
-
Institut Català de la Salut – Hospital Universitari de Bellvitge
-
Institut National de la Santé et de la Recherche Médicale
-
INSTITUTO NACIONAL DE SAUDE DR. RICARDO JORGE
-
Istituto Nazionale Malattie Infettive Lazzaro Spallanzani, IRCCS
-
JANSSEN PHARMACEUTICA NV
-
Klinikum der Universität zu Köln (AöR)
-
Leids Universitair Medisch Centrum
-
Linkopings Universitet
-
MEDIZINISCHE HOCHSCHULE HANNOVER
-
MEDIZINISCHE UNIVERSITAET WIEN
-
MINISTRIA E SHENDETESISE (National Institute of Public Health of Kosovo)
-
National Laboratory of Health, Environment and Food (SLOVENIA)
-
North Bristol National Health Service Trust
-
Pfizer
-
Radboud University Medical Center
-
Royal Liverpool and Broadgreen University Hospitals NHS Trust
-
Sanofi Recherche & Développement
-
Servicio Andaluz de Salud
-
SERVICIO MADRILENO DE SALUD
-
St George’s University of London
-
Stichting Katholieke Universiteit / Radboud University Nijmegen Medical Centre
-
Tel-Aviv Souraski MedicaI Center
-
Tel Aviv University
-
TranScrip Partners LLP
-
TWINCORE GmbH
-
UNIVERSITAET ULM
-
Universitair Ziekenhuis Antwerpen
-
UNIVERSITÄTSKLINIKUM FREIBURG
-
Universitätsklinikum Köln, AöR (University Hospital of Cologne)
-
UNIVERSITE CLAUDE BERNARD LYON 1
-
Université de Genève
-
Université de Poitiers
-
UNIVERSITE JOSEPH FOURIER, Centre de Recherche Inserm/UJF U823, Institut Albert Bonniot
-
Université Paris Diderot-Paris 7
-
University of Athens Medical School
-
University College London
-
University Medical Center Utrecht
-
University of Antwerp
-
University of Leeds
-
University of Liverpool
-
University of Zurich
-
University of the West of England